

## DAFTAR PUSTAKA

1. American Heart Association. 2000. High Blood Pressure. [Http://www.americanheart.org/Heart and Stroke Guide/hbp.html-11k](http://www.americanheart.org/HeartandStrokeGuide/hbp.html-11k).
2. Bustan MN. Hypertensive disease. Dalam; Epidemiologi penyakit tidak menular. PT Rineka Jakarta 1997; 31-8.
3. Arini S., Zunilda SB. Antihipertensi. Dalam; Farmakologi dan terapi, Eds IV Bagian Farmakologi FK UI, 1995; 315-41.
4. Raflizar. The problem of hypertension and its management. Dalam: Majalah Kedokteran Indonesia ( MKI ), 2000; (Vol 50 ): 56-60.
5. Boedhi Darmojo, R. Epidemiologi Hipertensi di Indonesia. Simposium Hipertensi, Surakarta 27 Februari 1991.
6. Murray CJL & Lopez AD., 1997. Mortality by cause for eight regions of the world: global burden of disease study. *Lancet*; 349: 1269-1276.
7. Wolf, P.A., Clagget, G.P. & Easton J.D. et al. 1999. Preventing ischemic stroke in patients with prior stroke and transients ischemic attack. A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke*; 30: 1991-1994.
8. Basuki S.& Lamsudin, R., 1994. Mortality of stroke in Yogyakarta, Indonesia, January 1, 1991 through December 31, 1991. Presented on First Asian-Ocean Symposium in Neuro-Epidemiology and Second Wu Ho-Su Memorial Lecture, 1994, Taipei.
9. Gorelick PB., Sacco RL., Smith DB., et al. 1999. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. *JAMA*; 281: 1112-1120.
10. World Health Organization. Management Guidelis. A mild Hypertension. *Medicine Digest*. June 1995: 2-8.
11. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 1997. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 1997. *Arch Intern Med*; 157: 2413-46.
12. Kaplan, N.M. 1983. Hypertension: Prevalence, risks, and effect of therapy. *Ann Intern Med*; 98: 7055-709.
13. Weder, A.B. 1997. Pathogenesis of hypertension: Genetic and environmental factors. In: Hollenberg NK, *Hypertension: Mechanisms and therapy. Atlas of heart disease*, Braunwald E, Chapter 1, p.1.
14. Kaplan, NM. 1998. Primary Hypertension: Pathogenesis. In: *Clinical Hypertension*, Kaplan NM, editor, 7<sup>th</sup> ed., chapter 3, p.41.
15. Bauer, J. & Reams, G. 1995. The angiotensin II type 1 receptor antagonist. A new class of antihypertensive drugs. *Arch Intern Med*; 155: 1361
16. Kang, P.M., Landau, A.J., Eberhardt, R.t. & Frishman, Angiotensin II receptor antagonist: A new approach to blockade

17. WHO. 1999. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee., *J Hypertension*; 17:151-184.
18. Sidabutar, R.P., Wiguno, P. 1990. Hipertensi Esensial. Dalam: Buku Ajar Ilmu Penyakit Dalam, Edisi II. Balai Penerbit Fakultas Kedokteran Indonesia. 205-223.
19. Cappuccio FP., 1997. Ethnicity and cardiovascular risk: variations in people of African ancestry and South Asian origin. *J Human Hypertens*; 1: 571-572.
20. Sheth T., Nair C., Nargundkar M., Anand S., Yusuf S., 1998. Cardiocascular and cancer mortality among Whites, South Asians, and Chinese in Canada from 1979 to 1993: An analysis of 2.6 million deaths. *Can Med Assoc J*; In press.
21. WHO-MONICA Project., Tunstall-Pedoe H., Kuvlasmaa K., Amouyel P., Arveiler D., Rajakangas AM., Pajak A. 1994. Myocardial infarction and coronary deaths in the Worlds Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation*; 90: 583-612.
22. Yao C., Wu Z., Wu Y. 1993. The changing pattern of cardiovascular disease in China. *Wld Hlth Statist Quart*; 46: 113-118.
23. Collins R., Peto R., Mac Mahon S., Herbert P., Fiebach NH., Eberlein KA., Godwin J., Qizibash N., Taylor JO., Hennekens CH. 1990. Blood pressure, stroke, and coronary hearth disease. Parth 2, shorth-term reductions in blood pressure: overview of randomised drug trials in their epodemiological context. *Lancet*; 335: 827-839.
24. Mac Mahon S., Rodgers A. 1997. The effects of antihypertensive treatment on vascular disease in Africa-American and white men. *JAMA*; 277: 1293-1298.
25. Leon AS., Myers MJ., Conett J., for the MRFIT Research Group. 1997. Leisure time physical activity and the 16-year risks of mortality from coronary hearth disease and all-cause in the Multiple Risk Factor Intervention Trial ( MRFIT ). *Int J Sports Med* ; 18 ( Suppl 3 ) : S208-S215.
26. Arakawa K., 1996. Effect of exercise on hypertension and associated complications. *Hypertens Res*; 19 ( Suppl ): S87-S91.
27. Grodstein F., Stampfer JJ., Colditz GA., Willett WC., Manson JE., Joffe M., Rosner B., Fuchs C., Hankinson SE., Hunter DJ., Hennekens CH., Speizer FE. 1997. Postmenopausal hormone therapy and mortality. *N Engl J Med*; 336: 1769-1775.
28. Hulley S., Grady D., Bush T., Furberg C., Herington D., Riggs B., Vittinghoff E. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary hearth disease in postmenopausal wome estrogen/progestin Replacement Study ( HERS ). *JAMA* ; 280: €
29. Davev-Smith G., Neaton JD., Wentworth D., Stamler R., Stai

- Multiple Risk Factor Intervention Trial: I. White men. *Am J Pub Health*; 86:486-496.
30. Whitelock G., Mac Mahon S., Vander Hoorn D., Davis P., Jackson R., Norton R. 1997. Socioeconomic distribution of smoking in a population of 10,529 New Zealanders. *NZ Med J*; 110: 327-330.
  31. Sheth T., Bosch J., Chen J., Anand S., Nargundkar M., Nair C., Yusuf S. 1997. Ethnic differences in socioeconomic status and mortality. 50 th annual meeting of the Canadian Cardiovascular Society. *Can J Cardiol*; 13 (Suppl C): 89 C.
  32. Tipene-Leach D., Stewart A., Beaglehole R. 1991. Coronary heart disease mortality in Auckland Maori and Europeans. *NZ Med J*; 104: 55-57.
  33. Lee EJ., Cowan LD., Welty TK., Sievers M., Howard WJ., Oopik A., Wang W., Yeh J., Devereux RB., Rhoades ER., Fabsitz RR., Go O., Howard BV. 1998. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-47 years, 1984-1988. The strong Heart Study. *Am J Epidemiol*; 147: 995-1008.
  34. Broderick J., Brott T., Kothari R., Miller R., Khaury J., Pancioli A., Gebel J., Mills D., Minneci L., Shukla R. 1998. The Greater Cincinnati/Northern Kentucky Stroke Study. Preliminary first-ever and total incidence rates of stroke among blacks. *Stroke*; 29: 415-421.
  35. Klag MJ., Whelton PK., Randall BL., Neaton JD., Brancati FL., Stamler J. 1997. End-stage renal disease in African-American and White men. *JAMA*; 277: 1293-1298.
  36. World Health Organization. World Health Statistics Annual. Geneva: World Health Organization, 1995.
  37. Sandok., Burton A., ( 1994 ), *Hypertension and The Brain*, Archive of Internal Medicine, vol.133.
  38. Mardjono M., Sidharta P., 1981, *Neurologi Klinis Dasar*, PT Dian Rakyat, Jakarta.
  39. Chandra B., 1994, *Patofisiologi dari stroke*. Simposium Stroke, Surakarta.
  40. Kase C. S., ( 1991 ), *Intracerebral hemorrhage*, dalam W. G. Bradley., R.B. Daroff., G.M. Fenichel, & C.D. Marsden: *Neurology in Clinical Practice*, vol. II, Butterworth-Heinemann, Boston PP 940-954.
  41. Ropper A. H & Schutz H, ( 1994 ), *Spontaneous intracerebral hemorrhage*, dalam W. Hacke: *Neurocritical Care*, Springer-Verlag Berlin, 621-31.
  42. Toole J.F., ( 1984 ), *Cerebrovascular Disorders*, 3 rd ed Raven Press Booke Ltd. New York.
  43. Collins R., Mac Mahon S., ( 1994 ), *Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease*, *Br Med Bull*, 50: 272-98.
  44. Darmoyo RB., 1977, Beberapa data epidemiologik hipertensi di Jawa Tengah, *Medika*; 2: 44-49.
  45. Lumbantobing SM., ( 1994 ) *Bencana Peredaran Darah di O*

46. Lamsudin R., ( 1996 ), Gangguan Peredaran Darah Otak. Dalam: Harsono et al. Buku Ajar Neurologi Klinis, edisi 1., 60, Gadjah Mada University Press, Yogyakarta.
47. Lamsudin R., ( 1996 ), Gangguan Peredaran Darah Otak. Dalam: Harsono et al. Buku Ajar Neurologi Klinis, edisi 1., 80-91, Gadjah Mada University Press, Yogyakarta.
48. Aliah A., Kuswara FF., Arifin RL et al., ( 1993 ), Gangguan Pembuluh Darah Otak. Dalam: Harsono et al. Kapita Selekta Neurologi, 25-34, Gadjah Mada University Press, Yogyakarta.
49. Spence JD., ( 1991 ), *Hypertension and stroke prevention*, dalam: Norris J W, Hachinski VC. Ed. Prevention of stroke. New York Inc: Springer-Verlag, 113-119.
50. De Keyser J., ( 1996 ), *Opportunities for neuroprotection*, Acut Stroke Management; ( 2 ): 11-14.
51. Stirling Meyer J., Takashima S., Terayama Y., (1992 ), *Current concepts of the role of neurotransmitters in the pathogenesis of cerebral infarction*, Ceramah di FK-UI, Januari, Jakarta.
52. Zivin JA., Choi DW., ( 1991 ), *Stroke therapy*, Scietific American; 265: 36-43.
53. Yatsu FM., ( 1996 Desember 9 ), *Acute ischemic stroke therapies*, KONAS III PERDOSSI.
54. Go K G., ( 1980 ), *Pathofysiologie fan de cerebrale ischemic*, dalam: Congres commissie van de Dr. GJ Van Heytema Stichting ed. Neurologie en Cerebrovasculair Ziekten. Twente, 20-22.
55. Burt, V.L., Whelton, P., Roccella, E.J., Brown, C., Cutler, J.A., Higgins, M., Horan, M.J & Labarthe D, 1995. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. *Hypertension*; 25: 305-313.
56. Klungel, O.H., Kaplan, R.C., Heckbert, S.R., Smith, N.I., Lemaitre, R.N., Longstreth, W.T., Leufkens, H.G., de Boer, A. & Patsy, B.M. 2000. Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. *Stroke*; 31: 420-424
57. Lamsudin R., 1996. Well controlled and less well controlled hypertension in stroke patients in Yogyakarta, Indonesia. *In Clin Epid & Biostat*; 3: 4-9.
58. Bullpitt, C.J., Rajkumar, C. & Beckett, N. 1999. *Clinician's manual. Hypertension and the elderly*. Science press Ltd., London, p 1-55.
59. Kaplan, N.M. 1998. Measurement of blood pressure. In: Clinical Hypertension, Kaplan NM, editor, 7<sup>th</sup> ed., chapter 2, p.19.
60. Cavalini, M.C., Roman, M.J. & Blank, S.G. 1996. Association of the auscultatory gap with vasculer disease in hypertensive patients. *Ann Intern Med*; 14: 877-83.
61. Kaplan, N.M. 1998. Primary Hypertension: Natural hist

63. Kaplan, N.M. 1998. Treatment of Hypertension: Drug Therapy. In: Clinical Hypertension, Kaplan NM, editor, 7<sup>th</sup> ed.,chapter 7, p.181.
64. Gress, T.W, Nieto, J.F., Shahar E, Wofford, M.R. & Brancati FL. 2000. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes melitus. *New Engl J Med*; 342: 905-12.
65. Hansson L, Lindholm LH, Niskanen L. *et al.* 1999.Effect of angiotensin converting-enzyme inhibition compared conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project ( CAPPP ) randomized trial. *Lancet*; 353: 611-16.
66. Asmar, R., Amah, G., Crisan, O. & Haddad, S. 1999. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension. *Eur Heart J*; 1 ( suppl.1 ): 21-30.
67. Weber, M. 1997. Clinical experience with the angiotensin II receptor antagonist losartan. Preliminary report. *Am J Hypertension*; 5: 247S-251S.
68. UK Prospective Study Group. 1998. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes melitus. *Br Med J*; 3117: 713-20.
69. Tschudi, M.R., Noll, G., Wenzel, R.R. & Luscher, T.F. 1997. Calcium antagonists and endothelial function: Interaction with Nitric Oxide and Endothelin. *J Cardiovasc Pharmacol*; 30 ( Suppl.3 ): S9-S17.
70. Israilli, Z.H. & Hall, W.D. 1992. Cough and angioneurotic edem associated with angiotensin- converting enzyme inhibitors therapy. A review of the literature and pathophysiology. *Ann Intern Med*; 117: 234-42.
71. Jackson , G. 1998. ACE inhibitors- a practical perspective. *Br J Cardiol*; 5: 588-594.
72. Bauer, J. & Reams, G. 1995. The angiotensin II type I receptor antagonist. A new class of antihypertensive drugs. *Arch Intern Med*; 155: 1361-8.
73. Urata, H., Nishimaru, H. & Ganten, D. 1996. Chymasedependent angiotensin II forming system in humans. *Am J Hypertension*; 9: 277-84
74. Higashiura, K., Ura, N., Miyazaki Y. & Shimamoto, K. 1999. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. *J Hum Hypertension*; 13:S71-S74.
75. Trenkwalder, P., Lehtovirta, M. & Dahl, K. 1997. Longterm treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. *J Hum Hypertension*; 11 ( Suppl 2 ): S81-S83.
76. Plum, J., Buntin, B., Nermeth, R. & Graabensee, B. 1998. Effect of angiotensin II antagonist valsartan on blood pressure, proteinuri, and renal haemodynamic in patients with cronic renal failure and hypertension. *JASN*; 9: 2223-34.
77. Jalowv. A., Schulz, R. & Heusch, G. 1999, AII receptor blockade in

78. Messerli, F., Grossman, E. & Goldbourt, U. 1998. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly ? a systematic review. *JAMA*; 279: 1903-1907.
79. Harper, G., Castelden, C.M. & Potter, J.F. 1994. Factors affecting changes in blood pressure after acute stroke. *Stroke* 1994; 1726-1729.
80. Morris, I., Schwartz, R. & Lykos, D, *et al.* 1995 Twenty hour ambulatory blood pressure profiles in the acute phase of stroke. *Clin Exp Pharmacol Physiol*; 22: 757-759.
81. Lamsudin, R., Misbach, J., Andradi, Cahyadi P., Hadinoto, S., Fauziah, & Suaryanto. 1997. Declining blood pressure spontaneously in acute ischemic stroke. *Ind J Clin Epid & Biostat*; 1: 8-12.
82. Broderick, J.P. 1996. Guideline for medical care and treatment of blood pressure in patients with acute stroke. *Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke*, December 12-13, 1996.
83. Helgason, C.M. & Wolf, P.A. 1997. American Heart Association Prevention Conference: Prevention and Rehabilitation of acute ischemic stroke. *Circulation*; 96: 701-707.
84. Gorelick PB, Sacco RL, Smith DB & et al. 1999. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the